Symbols / SPRB
SPRB Chart
About
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure, and SPR204, a monoclonal antibody antagonist for Post-Bariatric Hypoglycemia. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 62.32M |
| Enterprise Value | 48.03M | Income | -47.88M | Sales | 697.00K |
| Book/sh | 9.56 | Cash/sh | 9.97 | Dividend Yield | — |
| Payout | 0.00% | Employees | 9 | IPO | — |
| P/E | — | Forward P/E | -2.08 | PEG | — |
| P/S | 89.41 | P/B | 6.09 | P/C | — |
| EV/EBITDA | -0.97 | EV/Sales | 68.91 | Quick Ratio | 1.13 |
| Current Ratio | 1.54 | Debt/Eq | 25.03 | LT Debt/Eq | — |
| EPS (ttm) | -84.32 | EPS next Y | -28.05 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-10 16:00 | ROA | -76.92% |
| ROE | -167.93% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -71.00% | Profit Margin | 0.00% | Shs Outstand | 1.07M |
| Shs Float | 652.12K | Short Float | 6.77% | Short Ratio | 2.48 |
| Short Interest | — | 52W High | 2362.50 | 52W Low | 7.00 |
| Beta | 3.61 | Avg Volume | 59.90K | Volume | 34.76K |
| Target Price | $205.75 | Recom | Strong_buy | Prev Close | $55.15 |
| Price | $58.22 | Change | 5.57% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$205.75
Mean price target
2. Current target
$58.22
Latest analyst target
3. DCF / Fair value
$-518.96
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$58.22
Low
$160.00
High
$283.00
Mean
$205.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-19 | main | HC Wainwright & Co. | Buy → Buy | $200 |
| 2025-12-23 | init | Oppenheimer | — → Outperform | $283 |
| 2025-12-03 | up | Leerink Partners | Market Perform → Outperform | $160 |
| 2025-11-11 | main | Citizens | Market Outperform → Market Outperform | $259 |
| 2025-10-28 | up | JMP Securities | Market Perform → Market Outperform | $254 |
| 2025-10-21 | main | Leerink Partners | Market Perform → Market Perform | $160 |
| 2025-04-16 | main | RBC Capital | Sector Perform → Sector Perform | $1 |
| 2024-12-16 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-12-12 | reit | Guggenheim | Neutral → Neutral | — |
| 2024-12-11 | down | JMP Securities | Market Outperform → Market Perform | $3 |
| 2024-12-11 | reit | RBC Capital | Sector Perform → Sector Perform | $2 |
| 2024-12-11 | down | Oppenheimer | Outperform → Perform | — |
| 2024-11-12 | reit | RBC Capital | Sector Perform → Sector Perform | $2 |
| 2024-08-19 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-08-13 | reit | RBC Capital | Sector Perform → Sector Perform | $2 |
| 2024-06-13 | main | Oppenheimer | Outperform → Outperform | $3 |
| 2024-06-05 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-05-14 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-03-14 | down | RBC Capital | Outperform → Sector Perform | $2 |
| 2024-03-14 | down | HC Wainwright & Co. | Buy → Neutral | — |
- Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration - PR Newswire Sun, 18 Jan 2026 08
- Two drug veterans join push for rare disease treatment at Spruce - Stock Titan ue, 03 Feb 2026 08
- $SPRB stock is down 13% today. Here's what we see in our data. - Quiver Quantitative ue, 17 Feb 2026 19
- What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now? - Yahoo Finance Wed, 15 Oct 2025 07
- SPRB Analyst Rating Update: HC Wainwright Lowers Price Target | - GuruFocus hu, 19 Feb 2026 12
- Spruce Biosciences Stock Falls 5% Despite Positive Outcomes From Two Recent Type B Meetings With FDA - Nasdaq Wed, 18 Feb 2026 14
- With Spruce Biosciences Stock Sliding, Have You Assessed The Risk? - Trefis Sat, 20 Dec 2025 08
- SPRB Stock Hits 19-Month High Amid Trading Halts - Stocktwits ue, 07 Oct 2025 07
- Spruce Biosciences stock soars after receiving FDA Breakthrough Therapy status - Investing.com Mon, 06 Oct 2025 07
- FDA feedback boosts push for first disease-modifying option in MPS IIIB - Stock Titan Wed, 18 Feb 2026 12
- $SPRB stock is up 9% today. Here's what we see in our data. - Quiver Quantitative hu, 13 Nov 2025 08
- Spruce Biosciences (SPRB) Price Target Increased by 55.76% to 213.69 - Nasdaq Sat, 06 Dec 2025 08
- Biotech working on neurological drugs joins Oppenheimer stage - Stock Titan ue, 17 Feb 2026 21
- $SPRB stock is down 14% today. Here's what we see in our data. - Quiver Quantitative Mon, 27 Oct 2025 07
- Spruce Biosciences (SPRB) Price Target Increased by 2,045.14% to 137.19 - Nasdaq Mon, 17 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4690 | 408546.0 | — | Stock Award(Grant) at price 87.11 per share. | SZWARCBERG JAVIER B M.D. | Chief Executive Officer | — | 2025-12-31 00:00:00 | D |
| 1 | 1009 | nan | — | — | GHARIB SAMIR M | President | — | 2025-12-15 00:00:00 | D |
| 2 | 2676 | nan | — | — | SZWARCBERG JAVIER B M.D. | Chief Executive Officer | — | 2025-12-15 00:00:00 | D |
| 3 | 2414 | nan | — | — | GHARIB SAMIR M | President | — | 2025-12-11 00:00:00 | D |
| 4 | 1250 | nan | — | — | WAYS KIRK | Officer and Director | — | 2025-12-11 00:00:00 | D |
| 5 | 6146 | nan | — | — | SZWARCBERG JAVIER B M.D. | Chief Executive Officer | — | 2025-12-11 00:00:00 | D |
| 6 | 2053 | nan | — | — | GHARIB SAMIR M | President | — | 2025-10-20 00:00:00 | D |
| 7 | 4784 | nan | — | — | SZWARCBERG JAVIER B M.D. | Chief Executive Officer | — | 2025-10-20 00:00:00 | D |
| 8 | 256 | 33382.0 | — | Purchase at price 130.40 per share. | PARKMAN HEALTHCARE PARTNERS LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-06 00:00:00 | I |
| 9 | 257 | 33513.0 | — | Sale at price 130.40 per share. | PARKMAN HEALTHCARE PARTNERS LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-10-06 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -52.68M | -47.37M | -45.69M | -41.88M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -53.04M | -47.92M | -46.18M | -42.29M |
| ReconciledDepreciation | 46.00K | 70.00K | 74.00K | 68.00K |
| EBITDA | -52.68M | -47.37M | -45.69M | -41.88M |
| EBIT | -52.73M | -47.44M | -45.76M | -41.95M |
| NetInterestIncome | 3.12M | 4.07M | 1.10M | -226.00K |
| InterestExpense | 307.00K | 483.00K | 420.00K | 345.00K |
| InterestIncome | 3.42M | 4.56M | 1.52M | 119.00K |
| NormalizedIncome | -53.04M | -47.92M | -46.18M | -42.29M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -53.04M | -47.92M | -46.18M | -42.29M |
| TotalExpenses | 61.06M | 62.08M | 47.28M | 42.07M |
| TotalOperatingIncomeAsReported | -56.15M | -51.99M | -47.28M | -42.07M |
| DilutedAverageShares | 550.20K | 513.47K | 313.69K | 311.49K |
| BasicAverageShares | 550.20K | 513.47K | 313.69K | 311.49K |
| DilutedEPS | -96.75 | -93.00 | -147.00 | -135.75 |
| BasicEPS | -96.75 | -93.00 | -147.00 | -135.75 |
| DilutedNIAvailtoComStockholders | -53.04M | -47.92M | -46.18M | -42.29M |
| NetIncomeCommonStockholders | -53.04M | -47.92M | -46.18M | -42.29M |
| NetIncome | -53.04M | -47.92M | -46.18M | -42.29M |
| NetIncomeIncludingNoncontrollingInterests | -53.04M | -47.92M | -46.18M | -42.29M |
| NetIncomeContinuousOperations | -53.04M | -47.92M | -46.18M | -42.29M |
| PretaxIncome | -53.04M | -47.92M | -46.18M | -42.29M |
| OtherIncomeExpense | 119.00K | |||
| OtherNonOperatingIncomeExpenses | 119.00K | |||
| NetNonOperatingInterestIncomeExpense | 3.12M | 4.07M | 1.10M | -226.00K |
| InterestExpenseNonOperating | 307.00K | 483.00K | 420.00K | 345.00K |
| InterestIncomeNonOperating | 3.42M | 4.56M | 1.52M | 119.00K |
| OperatingIncome | -56.15M | -51.99M | -47.28M | -42.07M |
| OperatingExpense | 61.06M | 62.08M | 47.28M | 42.07M |
| ResearchAndDevelopment | 46.42M | 49.43M | 35.20M | 30.70M |
| SellingGeneralAndAdministration | 14.64M | 12.65M | 12.09M | 11.37M |
| GeneralAndAdministrativeExpense | 14.64M | 12.65M | 12.09M | 11.37M |
| OtherGandA | 14.64M | 12.65M | 12.09M | 11.37M |
| TotalRevenue | 4.91M | 10.09M | 0.00 | 0.00 |
| OperatingRevenue | 4.91M | 10.09M | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 563.08K | 547.06K | 314.68K | 313.23K |
| ShareIssued | 563.08K | 547.06K | 314.68K | 313.23K |
| TotalDebt | 2.77M | 4.61M | 6.32M | 6.53M |
| TangibleBookValue | 28.82M | 76.51M | 68.49M | 111.37M |
| InvestedCapital | 30.57M | 79.85M | 73.40M | 116.25M |
| WorkingCapital | 28.96M | 77.72M | 71.16M | 83.02M |
| NetTangibleAssets | 28.82M | 76.51M | 68.49M | 111.37M |
| CapitalLeaseObligations | 1.02M | 1.27M | 1.40M | 1.65M |
| CommonStockEquity | 28.82M | 76.51M | 68.49M | 111.37M |
| TotalCapitalization | 28.95M | 78.23M | 71.78M | 116.25M |
| TotalEquityGrossMinorityInterest | 28.82M | 76.51M | 68.49M | 111.37M |
| StockholdersEquity | 28.82M | 76.51M | 68.49M | 111.37M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | -558.00K | -184.00K | |
| OtherEquityAdjustments | -558.00K | -184.00K | ||
| RetainedEarnings | -250.27M | -197.23M | -149.31M | -103.13M |
| AdditionalPaidInCapital | 279.08M | 273.74M | 218.35M | 214.69M |
| CapitalStock | 4.00K | 4.00K | 3.00K | 3.00K |
| CommonStock | 4.00K | 4.00K | 3.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 16.39M | 27.44M | 17.16M | 15.12M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.14M | 2.97M | 4.71M | 6.24M |
| OtherNonCurrentLiabilities | 282.00K | 236.00K | 161.00K | 73.00K |
| LongTermDebtAndCapitalLeaseObligation | 860.00K | 2.74M | 4.55M | 6.17M |
| LongTermCapitalLeaseObligation | 736.00K | 1.02M | 1.26M | 1.29M |
| LongTermDebt | 124.00K | 1.72M | 3.29M | 4.88M |
| CurrentLiabilities | 15.25M | 24.46M | 12.45M | 8.87M |
| CurrentDeferredLiabilities | 0.00 | 4.91M | 0.00 | |
| CurrentDeferredRevenue | 0.00 | 4.91M | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 1.91M | 1.87M | 1.76M | 360.00K |
| CurrentCapitalLeaseObligation | 283.00K | 251.00K | 139.00K | 360.00K |
| CurrentDebt | 1.62M | 1.62M | 1.62M | |
| OtherCurrentBorrowings | 1.62M | 1.62M | 1.62M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 882.00K | 3.10M | 1.29M | 1.44M |
| PayablesAndAccruedExpenses | 12.46M | 14.58M | 9.40M | 7.08M |
| CurrentAccruedExpenses | 11.16M | 11.25M | 7.97M | 4.25M |
| Payables | 1.29M | 3.33M | 1.43M | 2.82M |
| AccountsPayable | 1.29M | 3.33M | 1.43M | 2.82M |
| TotalAssets | 45.21M | 103.95M | 85.65M | 126.49M |
| TotalNonCurrentAssets | 1.00M | 1.76M | 2.04M | 34.59M |
| OtherNonCurrentAssets | 69.00K | 582.00K | 640.00K | 653.00K |
| InvestmentsAndAdvances | 0.00 | 32.46M | ||
| NetPPE | 934.00K | 1.18M | 1.40M | 1.48M |
| GrossPPE | 934.00K | 1.18M | 1.40M | 1.48M |
| OtherProperties | 934.00K | 1.18M | 1.40M | 1.48M |
| CurrentAssets | 44.21M | 102.18M | 83.61M | 91.89M |
| OtherCurrentAssets | 2.28M | 1.97M | 1.21M | 396.00K |
| PrepaidAssets | 3.18M | 3.88M | 3.32M | 2.53M |
| CashCashEquivalentsAndShortTermInvestments | 38.75M | 96.34M | 79.08M | 88.97M |
| OtherShortTermInvestments | 0.00 | 54.59M | 46.22M | |
| CashAndCashEquivalents | 38.75M | 96.34M | 24.49M | 42.75M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -55.96M | -33.28M | -41.69M | -35.97M |
| RepaymentOfDebt | -1.62M | -1.62M | 0.00 | -4.77M |
| IssuanceOfDebt | 0.00 | 4.99M | ||
| IssuanceOfCapitalStock | 0.00 | 53.62M | 0.00 | 0.00 |
| CapitalExpenditure | -7.00K | -8.00K | -93.00K | |
| InterestPaidSupplementalData | 225.00K | 369.00K | 266.00K | 207.00K |
| EndCashPosition | 38.79M | 96.37M | 24.73M | 42.96M |
| BeginningCashPosition | 96.37M | 24.73M | 42.96M | 157.37M |
| ChangesInCash | -57.59M | 71.64M | -18.23M | -114.40M |
| FinancingCashFlow | -1.62M | 49.14M | -241.00K | 643.00K |
| CashFlowFromContinuingFinancingActivities | -1.62M | 49.14M | -241.00K | 643.00K |
| NetOtherFinancingCharges | -246.00K | -3.03M | -319.00K | -39.00K |
| ProceedsFromStockOptionExercised | 246.00K | 178.00K | 78.00K | 462.00K |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 0.00 | 53.62M | 0.00 | 0.00 |
| CommonStockIssuance | 0.00 | 53.62M | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | -1.62M | -1.62M | 0.00 | 220.00K |
| NetLongTermDebtIssuance | -1.62M | -1.62M | 0.00 | 220.00K |
| LongTermDebtPayments | -1.62M | -1.62M | 0.00 | -4.77M |
| LongTermDebtIssuance | 0.00 | 4.99M | ||
| InvestingCashFlow | 0.00 | 55.78M | 23.69M | -79.17M |
| CashFlowFromContinuingInvestingActivities | 0.00 | 55.78M | 23.69M | -79.17M |
| NetInvestmentPurchaseAndSale | 0.00 | 55.78M | 23.70M | -79.08M |
| SaleOfInvestment | 0.00 | 67.67M | 60.50M | 0.00 |
| PurchaseOfInvestment | 0.00 | -11.88M | -36.80M | -79.08M |
| NetPPEPurchaseAndSale | 0.00 | -7.00K | -8.00K | -93.00K |
| PurchaseOfPPE | 0.00 | -7.00K | -8.00K | -93.00K |
| OperatingCashFlow | -55.96M | -33.27M | -41.68M | -35.88M |
| CashFlowFromContinuingOperatingActivities | -55.96M | -33.27M | -41.68M | -35.88M |
| ChangeInWorkingCapital | -8.57M | 10.36M | 1.13M | 1.96M |
| ChangeInOtherWorkingCapital | -4.91M | 4.91M | 350.00K | |
| ChangeInOtherCurrentLiabilities | -237.00K | -176.00K | -331.00K | -156.00K |
| ChangeInOtherCurrentAssets | 494.00K | 96.00K | 90.00K | 197.00K |
| ChangeInPayablesAndAccruedExpense | -4.31M | 8.16M | 2.19M | 1.50M |
| ChangeInAccruedExpense | -2.27M | 6.25M | 3.59M | 2.30M |
| ChangeInPayable | -2.04M | 1.91M | -1.40M | -805.00K |
| ChangeInAccountPayable | -2.04M | 1.91M | -1.40M | -805.00K |
| ChangeInPrepaidAssets | 391.00K | -2.64M | -817.00K | 415.00K |
| OtherNonCashItems | 247.00K | 230.00K | -395.00K | 313.00K |
| StockBasedCompensation | 5.35M | 4.62M | 3.63M | 3.96M |
| AmortizationOfSecurities | 0.00 | -636.00K | 16.00K | 121.00K |
| DepreciationAmortizationDepletion | 46.00K | 70.00K | 74.00K | 68.00K |
| DepreciationAndAmortization | 46.00K | 70.00K | 74.00K | 68.00K |
| OperatingGainsLosses | 2.00K | 2.00K | 39.00K | |
| GainLossOnSaleOfPPE | 2.00K | 2.00K | 39.00K | 0.00 |
| NetIncomeFromContinuingOperations | -53.04M | -47.92M | -46.18M | -42.29M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SPRB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|